about
Positron emission tomography for radiation treatment planning.New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.Diagnosis of local recurrence after radical prostatectomy.Clinical Indications of C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse.Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT.Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases.Positron detection for the intraoperative localisation of cancer depositsDetection and compensation of organ/lesion motion using 4D-PET/CT respiratory gated acquisition techniques.Clinical evidence on PET/CT for radiation therapy planning in prostate cancer.The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.The role of PET/computed tomography scan in the management of prostate cancer.The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review.Motion management in positron emission tomography/computed tomography for radiation treatment planning.11C-choline PET/CT and PSA kinetics.Imaging biomarkers in prostate cancer: role of PET/CT and MRI.Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.FDG-PET/CT predicts outcome in oropharingeal carcinoma patients undergoing intensity modulated radiation therapy with dose escalation to FDG-avid tumour volumes.PET guidance in prostate cancer radiotherapy: Quantitative imaging to predict response and guide treatment.First Evaluation of PET-Based Human Biodistribution and Dosimetry of 18F-FAZA, a Tracer for Imaging Tumor Hypoxia.11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer.Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis.18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu's arteritis.PET imaging for lymph node dissection in prostate cancer.Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.Performance of beta- and high-energy gamma probes for the detection of cancer tissue in experimental surgical resection beds.Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography.Characterization of preclinical models of prostate cancer using PET-based molecular imaging.Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.FDG Uptake by Prosthetic Arterial Grafts in Large Vessel Vasculitis Is Not Specific for Active Disease.Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings.[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers.
P50
Q30996584-3040D09A-F9DC-42A0-BD3C-10327F38DE03Q34512641-850D6D08-C854-4FA7-9728-E1810175C615Q34532044-D52E14DC-4A7F-4CD6-B89C-CB00E0D98817Q34614216-66A5DDD4-A3D1-4E56-860C-86FAE90D65DFQ35685876-DE6EA3C2-23EA-466E-90F9-AF2FA89D739CQ35849174-B2911AE5-BD25-48E0-A898-75F3E3431AE0Q36320119-51D3D119-1857-4263-ABC3-885487759941Q36644372-A897548B-FAA6-46FE-8D3F-6697AC75225CQ36925038-490BA904-3CEE-4746-A10D-57DF1B0AB301Q37779904-031A616E-C2AE-470E-BB95-AAD5DF0785A1Q37779905-D15E1E5F-4C34-42C1-96D2-C5785F970D52Q37792304-275C5951-38F1-46FD-9F73-2E230F2DF300Q37850271-517A9587-24C2-42C4-8A46-1C3255F94F12Q38008241-153EB105-C80C-472F-AE88-5B813D7F0203Q38030104-EEA0B4B6-8A31-4E26-8010-EDCFD28A72AEQ38098442-704FB9B2-3B2E-499F-BB57-7F6C1DEA3B27Q38321182-D3F3FFFD-2603-47DC-81F1-A87215E6F446Q38564109-5CD72F66-8389-43CA-A0D1-0E6694F08A5AQ38729923-5C001534-EBC1-45C5-A75E-C2AB73065BB4Q38808751-4C9A0355-5961-4965-8B67-2AA65856F0BDQ38956387-468925F7-949B-428F-99BF-348035112571Q38970106-95054DB7-EC6B-49D9-A705-214EBC72D3CFQ38970109-280FF709-DCEE-4454-889E-15F6CA40E53EQ38970688-AAA3059A-F13D-42D2-93EA-4FE949189D1BQ38983526-E39E3947-84CE-4827-8DC7-FE5C9CE3D400Q39148442-6CE39646-33E8-451F-AC26-7339A1FB4D44Q39542074-A88B6161-9148-49EC-93DD-A89046E97767Q39839180-C1B2FD4A-D56F-4D49-B495-F70D5C14E1FEQ39874026-E3A3CF3A-0B1A-447C-84C5-D060A0CA99E1Q40126431-A950B4A6-3B68-4364-B9DA-F85A66A15AC7Q40363031-7505C371-F622-47D8-9631-A05A89A08F78Q40527607-5A5F5D50-6D4E-4256-A9D0-FF9EA06B0D5BQ40543305-21D2FCE2-EE40-4DD5-84DB-6CC9FEDC6CF2Q40765432-7AB8BB03-8368-4151-8051-045DC33C3242Q42164404-5821367D-3F07-4C5D-8E0C-1092B66B9C77Q42965590-849F3AD2-89E6-4AE5-BAC8-09682D82DE1CQ43122510-3919C8DC-ACD7-472B-99FF-2B0A4A28E913Q43157155-C4ABC43F-FA9C-4DFF-85FA-849013E1B22BQ43207980-D92AC237-FC6A-479B-993D-3128D07E9B1DQ43253773-0674FB22-ADBF-4E1A-BB69-3207BFEAA7E8
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maria Picchio
@ast
Maria Picchio
@en
Maria Picchio
@es
Maria Picchio
@nl
Maria Picchio
@sl
type
label
Maria Picchio
@ast
Maria Picchio
@en
Maria Picchio
@es
Maria Picchio
@nl
Maria Picchio
@sl
prefLabel
Maria Picchio
@ast
Maria Picchio
@en
Maria Picchio
@es
Maria Picchio
@nl
Maria Picchio
@sl
P108
P1053
K-4941-2016
P106
P108
P1153
7004198025
P21
P31
P3829
P496
0000-0002-7532-6211